Open AccessMoxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials
Author(s) -
Mingxia Sun,
Jinping Fan
Publication year - 2021
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm-20-2612
Subject(s) - moxifloxacin , medicine , randomized controlled trial , meta analysis , relative risk , regimen , confidence interval , sputum , tuberculosis , incidence (geometry) , surgery , antibiotics , pathology , microbiology and biotechnology , optics , physics , biology
Moxifloxacin is a fourth-generation fluoroquinolone that has shown good antibacterial activity against both gram-positive cocci and gram-negative bacteria. The purpose of this study was to evaluate the safety and efficacy of moxifloxacin in the drug treatment regimen of patients with tuberculosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom